Clinical Trials · NCT03201419
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 302
- Start date
- Jul 2017
- Locations
- 72 sites, 7 countries
- Primary endpoint
- Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment